Drug Trial Radar · NCT03548220
A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)
Last checked: Nov 19, 2026Latest source record: May 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
80
Actual
Start
Aug 9, 2018
Primary completion
Oct 9, 2020
Study completion Oct 9, 2020
Sponsor
- Lead sponsor
- Agios Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 7, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study AG348-C-006 evaluated the efficacy and safety of orally administered AG-348 as compared with placebo in participants with pyruvate kinase (PK) deficiency, who were not regularly receiving blood transfusions. Participants were randomized 1:1 to receive either AG-348 or a matching placebo.
Conditions
- Pyruvate Kinase Deficiency
- Anemia, Hemolytic
Interventions
PlaceboDrug
Placebo matching AG-348 tablets, administered to maintain the blind.
AG-348Drug
AG-348 tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving a Hemoglobin (Hb) Response (HR)Time frame: Baseline, Weeks 16, 20, 24
Locations
46 sites in 16 countries. Site status is shown where the registry gives one.
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Emory University
Atlanta, Georgia
Indiana Hemophilia and Thrombosis Center
Indianapolis, Indiana
Massachusetts General Hospital
Boston, Massachusetts
The Children's Hospital Corporation d/b/a Boston's Children Hospital
Boston, Massachusetts
Wayne State University School of Medicine, Children's Hospital of Michigan
Detroit, Michigan
Duke University
Durham, North Carolina
East Carolina University
Greenville, North Carolina
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Houston Methodist Research Institute
Houston, Texas
Primary Children's Hospital Univ. of Utah
Salt Lake City, Utah
Seattle Cancer Care Alliance
Seattle, Washington
Hospital Central da Faculdade de Medicina USP Cidade Universitaria
São Paulo, Brazil
McMaster University - Health Sciences Centre
Hamilton, Canada
Toronto General Hospital, University Health Network
Toronto, Canada
Institute of Hematology and Blood Transfusion
Prague, Czechia
University of Copenhagen, Herlev Hospital
Herlev, Denmark
CHU Amiens Picardie
Amiens, France
Hopital Saint-Andre
Bordeaux, France
Hôpital Henri-Mondor
Créteil, France
Hôpital de la Timone
Marseille, France
Institut Claudius Regaud
Toulouse, France
Charite University Medicine
Berlin, Germany
Universitätsklinikum Würzburg
Würzburg, Germany
Ospedale Galliera
Genova, Italy
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Milan, Italy
AOU Policlinico, Università della Campania "Luigi Vanvitelli"
Naples, Italy
Kyoto Katsura Hospital
Kyoto, Japan
Agios Investigative Site
Mie, Japan
Osaka City General Hospital
Osaka, Japan
Kansai Medical University, Department of Pediatrics, Hirakata Hospital
Osaka, Japan
Toho University Omori Medical Center
Tokyo, Japan
Tohoku University Hospital
Sendai, Miyagi, Japan
Universitair Medisch Centrum Utrecht
Utrecht, Netherlands
Yeungnam University Hospital
Daegu 705-703, South Korea
Hospital U. Vall d'Hebron Servicio de Hematología Clínica
Barcelona, Spain
Hospital Clinico Universitario Virgen de la Arricaxa
El Palmar, Spain
Hospital Universitario La Paz
Madrid, Spain
Centre Hospitalier Universitaire Vaudois (CHUV)
Lausanne, Switzerland
Department of Paediatrics and Thalassaemia Center, Faculty of Medicine Siriraj
Bangkok, Thailand
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.